Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

MT-1207

From Wikipedia, the free encyclopedia

Pharmaceutical compound
MT-1207
Clinical data
Other namesMT1207; II-13
Drug classSerotonin 5-HT2A receptor antagonist;α1-Adrenergic receptor antagonist;Calcium channel blocker
Pharmacokinetic data
Onset of action0.5–1.25 hours (TmaxTooltip time to peak levels)[1]
Eliminationhalf-life4–7 hours[1]
Identifiers
  • 3-[4-[4-(benzotriazol-1-yl)butyl]piperazin-1-yl]-1,2-benzothiazole
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H24N6S
Molar mass392.53 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCCN2C3=CC=CC=C3N=N2)C4=NSC5=CC=CC=C54
  • InChI=1S/C21H24N6S/c1-4-10-20-17(7-1)21(23-28-20)26-15-13-25(14-16-26)11-5-6-12-27-19-9-3-2-8-18(19)22-24-27/h1-4,7-10H,5-6,11-16H2
  • Key:GOALZWVIJQGFQJ-UHFFFAOYSA-N

MT-1207 is a combinedserotonin5-HT2A receptorantagonist,α1-adrenergic receptor antagonist, andcalcium channel blocker which is under development for the treatment ofhypertension (high blood pressure).[2][3][4][5][1] It is takenorally.[3] The drug'stime to peak levels is 0.5 to 1.25 hours and itselimination half-life is 4 to 7 hours.[1] MT-1207 is under development inChina.[3] As of 2025, MT-1207 has reachedphase 2clinical trials.[2][3]

References

[edit]
  1. ^abcdZhang H, Wu M, Hu Y, Li C, Zheng W, Liu J, et al. (March 2021). "Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects".Expert Opinion on Investigational Drugs.30 (3):271–278.doi:10.1080/13543784.2021.1887137.PMID 33560891.
  2. ^ab"Delving into the Latest Updates on MT-1207 with Synapse".Synapse. 12 January 2026. Retrieved18 January 2026.
  3. ^abcd"MT-1207 Drug Profile".Ozmosi. 1 January 1900. Retrieved18 January 2026.
  4. ^Wang P, Zhu H, Tian JS, Zhu W, Xu S, Yao H, et al. (September 2024)."Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension".Journal of Medicinal Chemistry.67 (18):16128–16144.doi:10.1021/acs.jmedchem.4c00626.PMID 38968440.
  5. ^Xu TY, Wang P, Tian JS, Qing SL, Wang SN, Huang YH, et al. (June 2021)."Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent".Acta Pharmacologica Sinica.42 (6):885–897.doi:10.1038/s41401-021-00636-1.PMC 8149631.PMID 33782540.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
Stub icon

Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MT-1207&oldid=1334645993"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp